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Case report
Subcutaneous sarcoidosis: a rare involvement
of the paralateral nasal region
Sarcoidosi sottocutanea: un raro caso di coinvolgimento della regione paralatero 
nasale
C. BianChini, E. Tosin, a. CiorBa, s. PEluCChi, a. PasTorE
EnT Department, university hospital of Ferrara, italy
SummAry
A case of subcutaneous sarcoidosis involving the paralateral nasal region is described and a brief review of the literature is made. Subcuta-
neous sarcoidosis without systemic disease is a rare entity and has seldom been reported on the trunk and face. Diagnosis is always difficult 
as it can only be confirmed by histological studies.
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riASSunTo
In questo articolo viene descritto un raro caso di sarcoidosi sottocutanea con coinvolgimento della regione paralatero-nasale e viene pre-
sentata una revisione della letteratura sull’argomento. La sarcoidosi sottocutanea senza interessamento sistemico è una patologia inusua-
le, e ancor più raramente è riportato il coinvolgimento del distretto cervico-facciale. La diagnosi di tale affezione può essere difficoltosa: 
necessita sempre della conferma istologica.
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Introduction
Subcutaneous sarcoidosis is a rare cutaneous expression 
of systemic sarcoidosis 1.
Sarcoidosis is a multisystem disorder characterized by the 
formation of non-caseating granulomas. it is reported to be 
caused by an oligoclonal response of CD4-positive T cells 
to an unknown antigen 2. The disorder may be manifested 
in numerous ways. in 90% of the patients, intra-thoracic 
involvement is revealed on chest radiography. other fre-
quently involved sites are the reticulo-endothelial system, 
the skin, and the eye. Sarcoidosis can also affect joints, 
muscles, exocrine and endocrine glands, the heart, the 
central nervous system, the upper respiratory tract, and 
the kidney 2.
Subcutaneous sarcoidosis is characterized by non-infec-
tious sarcoidal or epithelioid granulomas with minimal 
lymphocytic  inflammation  involving  predominantly  the 
panniculus. Subcutaneous involvement, over the extremi-
ties, occurs primarily in 20-35% of patients with systemic 
sarcoidosis, but may also occur without systemic disease. 
histological assessment is mandatory for a definitive di-
agnosis 3.
The rare case of subcutaneous sarcoidosis with paralateral 
nasal involvement is presented. 
Case report
A 38-year-old female was addressed to the enT Depart-
ment of the university hospital of Ferrara for the assess-
ment of a subcutaneous right paralateral nasal mass, also 
involving the suborbital region.
The patient had been complaining of a swelling in her 
right paralateral nasal region, associated with recurrent 
frontal  headache,  for  3  months.  She  had  already  been 
treated with systemic steroids (prednisone 25 mg/die for 
3 weeks) and antibiotics (ciprofloxacin 500 mg/die for 10 
days), which were unsuccessfull. Computed tomography 
(CT) scans and magnetic resonance imaging (mri) of the 
paranasal sinuses were performed (Fig. 1), disclosing a 
subcutaneous mass, about 1 cm in diameter, at the inferior 
edge of the right nasal bone. 
her past medical history revealed histological diagnosis 
of  erythema  nodosum  (en)  (right  leg),  when  she  was 
aged 21 years. She underwent an open septo/rhinoplasty 
when she was 33 (in another hospital).
At the examination, the lesion appeared nodular, non-ten-
der, firm and painful, in the right paralateral nasal region.
Serological testing for syphilis, anti-neutrophil cytoplas-
matic antibodies, and antinuclear antibodies all resulted 
negative.  Serum  angiotensin-converting  enzyme  (ACe) Subcutaneous sarcoidosis of the paralateral nasal region
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Fig. 3. At CT scan performed after 30 months of follow-up, no sign of lo-
cal recurrence has been observed, while the profile of the right nasal bone 
is almost normal.
Fig. 1. The paranasal sinuses CT (a) and MRI (b) scans revealed a subcutaneous mass about 1 cm in diameter, located at the inferior edge of the right nasal 
bone. Right nasal bone erosion can be detected at CT.
Fig. 2. In the specimen epithelioid cells together with multinucleate giant 
cells are visible. There are no signs of necrosis or of lymphocyte infiltration 
(H&E, x250).
was mildly elevated (85 nmol/ml; reference: 23-67 nmol/
ml). no other cutaneous or extra-cutaneous lesions were 
present and/or documented, in particular, chest X-ray and 
pulmonary CT scans were normal. Fundoscopy also re-
vealed no abnormalities.
A fine needle aspiration biopsy (FnAB) was promptly 
performed, but the cytological result was not conclusive 
(documented “aspecific cells”). The mass was then ex-
cised under general anaesthesia through a paralatero-na-
sal approach. upon reaching the subperiosteal plane, the 
lesion was gradually isolated, as the presence of a pseudo-
capsule facilitated the separation of the mass from the sur-
rounding tissue. The mass was then removed.
The histological analysis indicated sarcoidosis; it revealed 
a nodular inflammatory mass limited to the subcutaneous 
tissue,  composed  of  epithelioid  granulomas,  few  giant 
cells and hyalinosis. Stains and cultures for mycobacteria 
and fungi were negative (Fig. 2).
The  patient  was  addressed  to  the  rheumatology  unit 
where she was treated with prednisone 12.5 mg/die and 
this  treatment  has  been  maintained  till  now. After  30 
months’ of follow-up, no signs of local recurrence have 
been observed (Fig. 3) and, so far, no other localizations 
of disease have been reported. 
Discussion and conclusions
Sarcoidosis is a multisystem disease defined by the for-
mation of non-caseating granulomas in various organs. 
The diagnosis is well established when clinical and ra-
diological findings are supported by histological evidence 
of  non-caseating  granulomas  in  one  or  more  tissues 4. 
Subcutaneous involvement occurs in 20-35% of patients 
with systemic sarcoidosis but may also occur alone with-
out systemic disease 1. Subcutaneous sarcoidosis alone is 
defined as a rare manifestation of sarcoidosis 1. Darier and 
roussy reported the first case of subcutaneous sarcoidosis 
in 1904 5. vainsencher and Winkelmann, in 1984, reported C. Bianchini et al.
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4 cases of subcutaneous sarcoidosis, 3 of which showed 
systemic involvement 1. it is reported to occur mainly in 
women, most often in their fifth or sixth decades 6.
The diagnosis of subcutaneous sarcoidosis is difficult to 
achieve and can only be confirmed by histological stud-
ies. various non-specific laboratory abnormalities may be 
seen, such as an elevated erythrocyte sedimentation rate 
and  hyper-gamma-globulinaemia 2.  An  elevated  serum 
angiotensin-converting enzyme (ACe) level is reported 
to have a sensitivity of 40-90% and a positive predictive 
value of up to 90% but may be falsely positive in several 
other granulomatous diseases, hyperthyroidism, liver cir-
rhosis, diabetes mellitus, and gaucher’s disease. Further-
more, it may be falsely negative when ACe inhibitors are 
used 2 7. other reported laboratory abnormalities include 
hypercalcaemia and hypercalciuria (2-63%) 2. A specific 
diagnostic test is the Kveim-Siltzbach skin test that has 
a reported sensitivity of 30-96% and is not widely used 2. 
The histological assessment is mandatory for a definitive 
diagnosis 3, as in the case presented here. 
The  association  between  subcutaneous  sarcoidosis  and 
en, as in this case, is not frequently reported and some 
Authors describe the occurrence of en as a first manifes-
tation of immunologic disease 8-10.
moreover,  the  present  case  report  illustrates  a  rare  lo-
calization of subcutaneous sarcoidosis, as the nodules are 
mainly distributed over the extremities (upper extremi-
ties, mainly in the forearms, and usually are bilateral and 
asymmetric) and rarely on the trunk and face 8 11.
Differential diagnosis includes lipoma, lupus vulgaris, lep-
rosy, rosacea, granuloma, reaction to foreign bodies 9 12.
At present, there is no curative treatment for sarcoidosis. 
immunosuppressive  and/or  immunomodulatory  drugs, 
however, are used for controlling the disease, with cor-
ticosteroids remaining the mainstay of treatment. They 
function by suppressing the pro-inflammatory cytokines 
and chemokines that are involved in cell-mediated im-
mune responses and granuloma formation. methotrexate 
or hydroxychloroquine may be added, especially if the re-
sponse to steroids is inadequate. Although the chemokine 
and cytokine pathways that regulate granuloma formation 
are  not  well  understood,  tumour  necrosis  factor-alpha 
(TnFa) is implicated. TnFa antagonists such as pentoxi-
fylline and thalidomide are reported to be useful in refrac-
tory systemic disease and neurosarcoidosis. infliximab (a 
monoclonal antibody against TnFa) in particular has a 
growing body of literature supporting its effectiveness, 
and appears to be a safe treatment approach with a good 
steroid-sparing effect 13 14.
in the case reported here, the paralateral nasal nodule was 
the only one that occurred, and the long-term treatment with 
steroids seems to be effective in controlling the disease.
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